Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

This is a real-world observational study in South Korea that follows women with endometrial cancer (cancer of the lining of the uterus) who are being treated with durvalumab — an immunotherapy drug — with or without olaparib (a targeted therapy that blocks cancer cell DNA repair). Both drugs are approved for use in Korea. The study monitors how patients do in everyday clinical practice, including any side effects and how well the disease is controlled over time. **You may be eligible if...** - You have endometrial cancer and are receiving durvalumab (with or without olaparib) as prescribed under the approved Korean guidelines - You have provided signed informed consent **You may NOT be eligible if...** - You are participating in another interventional clinical trial at the same time - You are using these medications for a purpose not approved on the Korean drug label Talk to your doctor to see if this trial is right for you.